SEARCH

SEARCH BY CITATION

Keywords:

  • prostate cancer;
  • castration resistance;
  • androgen deprivation;
  • novel endocrine therapy;
  • hormone refractory;
  • androgen receptor

Abstract

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. THE NORMAL PROSTATE AND THE AR
  5. PROSTATE CANCER: THE ROLE OF ANDROGEN AND AR
  6. LIGAND-DEPENDENT MECHANISMS OF CASTRATION RESISTANCE
  7. LIGAND-INDEPENDENT MECHANISMS OF CASTRATION RESISTANCE
  8. NOVEL ENDOCRINE THERAPIES
  9. SUMMARY
  10. CONFLICT OF INTEREST
  11. REFERENCES

What's known on the subject? and What does the study add?

Castration resistance has been appreciated for decades, and several mechanisms theorising on this effect have been proposed. A rich pipeline of novel agents, including abiraterone and MDV3100, have provided proof of principle that novel agents targeting the AR signalling pathway with superior selectivity and activity than predecessors have yielded significant clinical benefit for patients with metastatic castration-resistant prostate cancer.

Our review provides an update in the development of several novel agents targeting the AR signalling pathway now in clinical testing, as well as review novel therapies in development with distinct mechanisms of action showing promising preclinical activity.

  • • 
    Despite undergoing local therapy with curative intent, 20–30% of patients with prostate cancer will ultimately development metastatic disease, leading to morbidity and mortality.
  • • 
    Androgen-deprivation therapy (ADT) for men with metastatic prostate cancer results in transient clinical benefit, but ultimately, cancers progress despite castrate levels of serum testosterone, a clinical state classically referred to as ‘hormone refractory’ disease.
  • • 
    In this review, we examine mechanisms of resistance to ADT that have redefined our understanding of the more appropriately termed ‘castration resistant’ disease, and have paved the way for a new generation of therapeutics targeting the androgen signalling axis in advanced prostate cancer.

Abbreviations
ADT

androgen-deprivation therapy

AE

adverse event

AR

androgen receptor

ASCO

American Society of Clinical Oncology

CRPC

castration-resistant prostate cancer

CTD

COOH-terminal domain

DHEA

dehydroepiandrosterone

DHT

dihydrotestosterone

FDA

USA Food and Drug Administration

HDAC(i)

histone deacetylase (inhibitors)

hsp

heat-shock protein

NTD

N-terminal domain

INTRODUCTION

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. THE NORMAL PROSTATE AND THE AR
  5. PROSTATE CANCER: THE ROLE OF ANDROGEN AND AR
  6. LIGAND-DEPENDENT MECHANISMS OF CASTRATION RESISTANCE
  7. LIGAND-INDEPENDENT MECHANISMS OF CASTRATION RESISTANCE
  8. NOVEL ENDOCRINE THERAPIES
  9. SUMMARY
  10. CONFLICT OF INTEREST
  11. REFERENCES

Prostate cancer is the most common non-skin cancer in men in the Western world [1]. While widespread PSA screening has significantly increased prostate cancer detection, about one-third of men treated with definitive local therapy will have disease recurrence, while another subset will present with advanced disease at the time of initial diagnosis [2]. Prostate cancer growth and progression is stimulated by androgens, acting through the androgen receptor (AR). Circulating androgen levels are predominately regulated through the hypothalamic-pituitary-adrenal-gonadal axis and androgen-deprivation therapy (ADT) results in temporary disease regression in most patients. However, this approach eventually fails, as tumours develop mechanisms to grow despite chemical or surgical castration and inevitably leading to significant morbidity and mortality.

THE NORMAL PROSTATE AND THE AR

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. THE NORMAL PROSTATE AND THE AR
  5. PROSTATE CANCER: THE ROLE OF ANDROGEN AND AR
  6. LIGAND-DEPENDENT MECHANISMS OF CASTRATION RESISTANCE
  7. LIGAND-INDEPENDENT MECHANISMS OF CASTRATION RESISTANCE
  8. NOVEL ENDOCRINE THERAPIES
  9. SUMMARY
  10. CONFLICT OF INTEREST
  11. REFERENCES

The prostate is responsible for producing most of the fluid in the seminal plasma volume of men's ejaculate. Binding of androgens to the AR, expressed in epithelial and stromal cells of the prostate [3], results in differentiation, metabolism, proliferation, and survival of these cells. The AR is composed of ligand-dependent intracellular transcription factors that are known to influence the development and growth of prostate cancer. Mouse models show that androgens are required at every step of prostate development [4], as a non-functional AR results in a testicular feminisation-like syndrome with absence of the prostate [5]. While androgens are produced by both the Leydig cells of the testes (testosterone: 90–95%) and adrenal gland (5-dehydroepiandrosterone [DHEA] and androstenedione: 5–10%), conversion to dihydrotestosterone (DHT) by 5α-reductase occurs in the prostate.

The AR has three main regions: the N-terminal domain (NTD), which contains the activation function; a central DNA binding domain; and a COOH-terminal domain (CTD), which contains the ligand-binding region. The AR is a nuclear hormone receptor normally bound in a complex with multiple chaperones (heat-shock proteins, hsps). Upon androgen binding, AR changes its conformation, leading to nuclear translocation and subsequent dimerization with androgen response elements in the promoter and enhancer regions of target genes [6]. Through cytoplasmic signalling [7–9] and recruitment of co-activator proteins [10], target gene transcription is enhanced, which leads to cellular proliferation.

PROSTATE CANCER: THE ROLE OF ANDROGEN AND AR

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. THE NORMAL PROSTATE AND THE AR
  5. PROSTATE CANCER: THE ROLE OF ANDROGEN AND AR
  6. LIGAND-DEPENDENT MECHANISMS OF CASTRATION RESISTANCE
  7. LIGAND-INDEPENDENT MECHANISMS OF CASTRATION RESISTANCE
  8. NOVEL ENDOCRINE THERAPIES
  9. SUMMARY
  10. CONFLICT OF INTEREST
  11. REFERENCES

Since the work of Huggins and Hodges demonstrated regression of metastatic prostate cancer with surgical castration in the 1940s, manoeuvres to deplete androgens have remained the standard first-line treatment for metastatic disease. However, this strategy ultimately fails as tumours develop mechanisms to grow despite low levels of circulating androgens.

Whether resistant prostate cancer clones exist before the initiation of ADT is not known [11]. With ADT, selective pressure selects for androgen-resistant clones preferentially to proliferate. Additional molecular changes may cause resistant populations of cells to become dominant, leading to state known as castration-resistant prostate cancer (CRPC). Several mechanisms of castration resistance have been proposed, classified broadly as either ligand-dependent or ligand-independent pathways (Fig. 1). The clinical management of patients with CRPC is challenging, as several of these mechanisms may be involved simultaneously in any given patient.

image

Figure 1. AR signalling and mechanisms of castration resistance.

Download figure to PowerPoint

LIGAND-DEPENDENT MECHANISMS OF CASTRATION RESISTANCE

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. THE NORMAL PROSTATE AND THE AR
  5. PROSTATE CANCER: THE ROLE OF ANDROGEN AND AR
  6. LIGAND-DEPENDENT MECHANISMS OF CASTRATION RESISTANCE
  7. LIGAND-INDEPENDENT MECHANISMS OF CASTRATION RESISTANCE
  8. NOVEL ENDOCRINE THERAPIES
  9. SUMMARY
  10. CONFLICT OF INTEREST
  11. REFERENCES

Persistent androgens despite castration

Despite castration, alterations in the multi-step processing of androgen synthesis and transport can provide high enough concentrations of androgens in the tumour microenvironment to drive tumour growth and progression. The clinical efficacy of secondary hormonal agents targeting the androgen–AR axis after progression despite castration has provided a proof of principle that residual androgens can stimulate continued tumour proliferation. Both adrenal and intra-tumoral androgens have been recognised to play an essential role in the development of CRPC [12]. Polymorphisms in androgen conversion and transportation have also been associated with outcomes in CRPC [13]. Furthermore, a recent study showed that DHT synthesis may bypass testosterone in driving castration resistance [14]. Taken together, these findings highlight the multiple steps in the pathway of androgen synthesis and transport that can be commandeered by tumour cells to maintain adequate levels of androgens in the microenvironment to support growth.

The adrenal glands have long been recognised as a potential source of androgen production despite surgical or chemical castration. Early attempts to maximize adrenal androgen blockade via adrenalectomy had limited efficacy [15]. Subsequently, the antifungal ketoconazole, a cytochrome P450 and 17,20-lyase inhibitor blocking the synthesis and degradation of adrenal steroids, was used to treat men with CRPC confirming the importance of extra-testicular sources of androgen production in subsets of patients [16]. The clinical activity of ketoconazole also provided the conceptual, and molecular, framework for the development of more selective adrenal androgen inhibitors.

More recently, the importance of intratumoral androgen production has emerged. Several studies showed that despite castrate levels of serum testosterone, residual levels of testosterone remain sufficiently elevated in the prostate cancer microenvironment, suggesting an ‘autocrine’ pathway of androgen production may play an important role in developing castration resistance [12]. Selective stress from castration causes prostate cancer to up-regulate enzymes responsible for de novo steroidogenesis and adrenal steroid conversion and fuel intra-prostatic androgen [17–21].

AR gene amplification

Compared with hormone-sensitive prostate cancer cells, up to one-third of CRPC tumours harbour AR gene amplification [22–24]. Despite castration, AR hypersensitivity to low levels of androgens results in continued tumour proliferation [23,25]. In addition, heightened AR sensitivity to DHT is associated with increased AR expression, stability, and nuclear localisation in CRPC cells [26]. Therapeutic use of AR blockade may also lead to AR over-expression and hypersensitivity [27].

LIGAND-INDEPENDENT MECHANISMS OF CASTRATION RESISTANCE

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. THE NORMAL PROSTATE AND THE AR
  5. PROSTATE CANCER: THE ROLE OF ANDROGEN AND AR
  6. LIGAND-DEPENDENT MECHANISMS OF CASTRATION RESISTANCE
  7. LIGAND-INDEPENDENT MECHANISMS OF CASTRATION RESISTANCE
  8. NOVEL ENDOCRINE THERAPIES
  9. SUMMARY
  10. CONFLICT OF INTEREST
  11. REFERENCES

Conventional hormonal therapy is ineffective when tumours grow in a truly androgen independent manner, thus posing a major clinical challenge, particularly as more potent and selective androgen biosynthesis inhibitors and AR blockers emerge. Several mechanisms have been hypothesised to play important roles in the development of castration resistance including genetic variations, epigenetic changes, and alteration of transcriptional and translational regulation, leading to tumour proliferation without ligand binding.

AR mutations

Although AR mutations are uncommon in CRPC, it has been speculated that AR is activated by several hormones, including progesterone, oestrogen, adrenal androgens and metabolic by-products of DHT [28–30]. In addition, mutant ARs may also bind AR antagonists [31,32], as well as corticosteroids [33]. The promiscuous nature of the mutant AR may be responsible for the anti-androgen withdrawal syndrome, whereby patients with progressive disease on an anti-androgen experience a transient disease remission simply by discontinuing the anti-androgen. In these cases, the drug was presumably exerting agonistic, rather than antagonistic functions [34].

Epigenetic modification

Recent work has shown that epigenetics may play an important role in the development of CRPC [35]. Preclinical models have shown that post-translational modifications, e.g. histone modification and DNA methylation, can lead to castration resistance [36]. DNA hypermethylation down-regulates the AR suppressor binding complex leading to increased AR expression [37], while DNA hypomethylation during androgen deprivation increases AR signalling in CRPC [38]. Adaptor/scaffolding protein receptor for activated C kinase 1 (RACK1), via binding to the tyrosine kinase Src, modulates the tyrosine phosphorylation of AR, facilitating AR translocation. This process is ligand independent, resulting in up-regulation of transcriptional activity in hormonally treated prostate cancer cells [39]. AR-mediated transcriptional activation of several proliferation and apoptotic pathways is critically dependent on histone acetylation [40]. Novel therapeutic strategies targeting these post-translational modifications are now being investigated in clinical trials, although early trials of these agents have not yet shown significant clinical activity [41,42].

AR splice variants

AR splice variants ARs have been hypothesised to contribute to the development of CRPC [43]. Under normal conditions, the androgen-AR complex will translocate into the nucleus, and regulate expression of androgen-responsive genes. However, AR splice variant isoforms are constitutively active, promoting tumour cell growth independently of ligand [44]. Recent work has shown that the AR signalling inhibitor MDV3100 inhibits the growth of prostate cancer cell lines harbouring some AR splice variants [45].

AR co-activators and co-repressors

Upon binding with androgen, AR recruits co-regulatory proteins, which include chromatin-remodelling complexes and transcription machinery that leads to modulation of transcription. Several AR co-activators have been identified as major contributors to the development of CRPC. In the setting of castration, co-activators such as hsp27 [46,47], Her2Neu tyrosine kinase [48], bcl-2 [49], and IGF-binding protein 5 [50] are up-regulated, and associated with the development of castration resistance. Likewise, co-repressors have been described in AR regulation [51], with mechanisms such as direct sequestration by DAX-1 [42], and interruption of AR C- and N-terminal interaction by Filamin-A [52,53].

NOVEL ENDOCRINE THERAPIES

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. THE NORMAL PROSTATE AND THE AR
  5. PROSTATE CANCER: THE ROLE OF ANDROGEN AND AR
  6. LIGAND-DEPENDENT MECHANISMS OF CASTRATION RESISTANCE
  7. LIGAND-INDEPENDENT MECHANISMS OF CASTRATION RESISTANCE
  8. NOVEL ENDOCRINE THERAPIES
  9. SUMMARY
  10. CONFLICT OF INTEREST
  11. REFERENCES

With a better understanding of the mechanisms resulting in castration resistance, novel therapeutic agents that target residual androgen and the AR signalling axis have shown significant preclinical activity, and have rapidly entered clinical testing (Table 1). Already, Zytiga (abiraterone acetate) and Enzalutamide (MDV3100) have both been shown to improve survival in patients with CRPC (Table 2).

Table 1.  Mechanisms of novel AR-targeted agents in clinical development
Mechanism of castration resistanceDrug actionNovel drugs
Ligand dependent  
 Residual androgens (adrenal + intratumoral)CYP17 inhibitionAbiraterone
17,20-lyase inhibitorTAK-700
Analogue of 3β-androstanediol (d-cholesterol -x- > d-pregnenolone)Apoptone
CYP17 inhibition + AR antagonistTOK-001
 AR binding (gene amplification)AR antagonist + AR translocation inhibitorMDV3100/ARN509
Analogue of 3β-androstanediol (AR antagonist)Apoptone
CYP17 inhibition + AR antagonistTOK-001
Targets AR NTDEPI-001
Ligand independent  
 Constitutively active AR splice variantsAR antagonist + AR translocation inhibitorMDV3100
 Epigenetic modificationsAnti-AR mRNAEZN4176
HDACiPanobinostat
Hypomethylating agentAzacitidine
Table 2.  Recent and on-going Phase III clinical trials of novel agents targeting AR signalling axis
Clinical TrialAgentNo. of patientsCriteriaPrimary endpointOutcome/primary completion date
  1. PFS, progression-free survival; OS, overall survival.

COU-301Abiraterone1000Post-DocetaxelOSFavourable OS
COU-302Abiraterone1158Pre-DocetaxelOSFavourable PFS
Study Un-blinded
AFFIRMMDV31001199Post-DocetaxelOSFavourable OS
PREVAILMDV31001680Pre-DocetaxelOS, PFSSeptember, 2014
NCT01193244TAK-7001083Post-DocetaxelOS, PFSOctober, 2013
NCT00716794TAK-7001454Pre-DocetaxelOS, PFSJanuary, 2013

Abiraterone acetate

Abiraterone acetate, an irreversible inhibitor of cytochrome p450 complex CYP17, is an oral agent that suppresses adrenal steroid and intra-tumoral androgen synthesis. Compared with its predecessor ketoconazole, abiraterone is both more potent and selective. In a phase I study, abiraterone administered at multiple dose levels resulted in marked reductions in serum testosterone levels to <1 ng/dL, and resulted in regression of measurable disease [54]. Because mineralocorticoids increased and resulted in related adverse events (AEs), e.g. hypertension, hypokalaemia, leg swelling, adding epleronone was effective in ameliorating these events. Responses were also seen in patients previously receiving ketoconazole in a second phase I study [55].

Two phase II trials using abiraterone 1000 mg and prednisone 10 mg daily further demonstrated the favourable tolerability and clinical activity in the treatment of CRPC. In patients who were chemotherapy naïve, 67% had a PSA level decline of >50%, 37.5% of patients with measurable disease had partial response by RECIST criteria, and 66% had stable disease at 6 months [56]. However, secondary mineralocorticoid excess resulted in significant hypokalaemia (88%), hypertension (40%), and fluid overload (31%), necessitating eplerenone treatment. A separate study evaluated patients with CRPC that had previously received docetaxel [57]. Even in this heavily pre-treated population, 36% of the patients had >50% PSA level declines, 18% of the patients had partial radiographic response, and the median time to PSA progression was 169 days. Importantly, with the co-administration of 10 mg oral prednisone, clinical manifestations of mineralocorticoid excess were not observed.

Two large phase III randomised trials of abiraterone were initiated to evaluate two separate patient populations. COU-AA-301 randomised 1195 patients in a 2:1 ratio to treatment with abiraterone and prednisone in patients with CRPC who previously received docetaxel. The combined treatment arm showed a statistically significant overall survival benefit (14.8 vs 10.9 months, hazard ratio [HR] 0.65, P < 0.001) [58]. In addition, other clinical endpoints, including time to PSA progression (10.2 vs 6.6 months, HR 0.58, P < 0.001), radiographic progression-free survival (5.6 vs 3.6 months, P < 0.001), and PSA response (38% vs 10%, P < 0.001), favoured the combined treatment arm. Abiraterone was associated with increased AEs, including fluid retention, hypokalaemia, hypertension, transaminitis, and cardiac dysfunction in the combined treatment arm, generally low-grade and manageable. COU-AA-302 is a double-blinded, placebo-controlled, phase III study that randomised 1088 patients with chemotherapy naïve CRPC to compare abiraterone 1000 mg and prednisone 10 mg daily vs prednisone alone. A recent press release of the interim analysis by an independent monitoring committee concluded that differences in radiographic progression-free survival, overall survival, and secondary endpoints favoured the combined treatment arm [59].

MDV3100

Several lines of evidence suggest that AR amplification is common in CRPC and may confer therapeutic resistance to conventional anti-androgens [60]. MDV3100 was developed based on preclinical activity even in the presence of AR amplification [61]. Compared with older generation non-steroidal anti-androgens, MDV3100 has greater affinity for AR, and in addition inhibits AR nuclear translocation without detectable agonist effects. In a phase I–II study, escalating doses of MDV3100 were evaluated in patients with progressive CRPC [62]. A dose of 240 mg/day was selected for further investigation, as higher doses increased the risk of seizures. In the phase II portion, administration of MDV3100 achieved PSA level declines of >50% in 56% of patients and radiographic responses in 22% of patients. Circulating tumour cell counts showed 49% (25/51) of patients converting from an unfavourable count before treatment (>5 cells/7.5 mL blood) to a favourable count after treatment (<5 cells/7.5 mL blood) [63]. Interestingly, PET imaging with 18F-fluoro-5α-DHT showed decreased androgen to AR binding, confirming the original hypothesised mechanism of action. Two randomised, placebo-controlled, phase III trials of MDV3100 have been conducted, evaluating its efficacy in patients with both pre- (PREVAIL) and post-docetaxel CRPC (AFFIRM). Recently reported interim analysis of the AFFIRM trial, which randomised 1199 patients in a 1:1 ratio, showed that estimated median survival was 18.4 months for men treated with MDV3100 compared with 13.6 months for men treated with placebo (P < 0.001), with a 37% reduction in the risk of death with MDV3100 [64].

TAK-700

TAK-700 is a 17, 20-lyase inhibitor that significantly reduces adrenal and testicular androgen levels. After showing significant in vitro activity against prostate cancer cell lines, a phase I/II, dose-escalation study was initiated. TAK-700 was administered at five dose levels, with prednisone 5 mg twice daily. With additional patients treated at a dose of 400 mg twice daily, dose limiting toxicity was seen. The most common AEs were fatigue (17 patients, three grade ≥3 with 600 mg twice a day), nausea (11 patients, one grade 3), and vomiting (seven patients, two grade ≥3). Pharmacokinetic analysis showed dose proportional increases in single and multiple dose maximum plasma concentrations of the drug (Cmax) and the area under the concentration–time curve (AUC0–8h). Impressively, the median testosterone and DHEA sulphate levels decreased from 5.5 to 0.6 ng/dL and from 50.0 µg/dL to below quantifiable levels, respectively. All patients treated with ≥300 mg doses had a PSA level decrease and in patients who received at least three cycles of TAK-700 ≥300 mg, 12 (80%) had PSA level reductions of ≥50% and four (27%) had reductions of ≥90%. Given its efficacy and safety, two randomised, placebo-controlled, phase III trials have been initiated to evaluate TAK-700 with prednisone in patients with metastatic CRPC in the docetaxel-naïve and docetaxel-treated populations.

Apoptone

Apoptone, also known as HE3235, is a novel synthetic analogue of 3β-androstanediol that has shown significant preclinical activity against prostate and breast cancer [65]. In cell lines, apoptone binds to ARs, resulting in the down-regulation of Bcl-2 and increased expression of caspases. In human prostate adenocarcinoma cell lines, apoptone decreased AR expression, and in a CRPC xenograft suppressed tumour growth and tumoral androgen synthesis. Additionally, independent of CYP17 inhibition, apoptone inhibits conversion of d-cholesterol to d-pregnenolone. An on-going phase I/II study is exploring the pharmacokinetics, safety, and activity of apoptone in patients with both chemo-naïve and chemotherapy-treated metastatic CRPC [66–68].

Epigenetic therapy

Histone deacetylase inhibitors (HDACi), via modulation of HDAC activity, have a broad spectrum of epigenetic activities that have yet to be fully defined. SAHA, also known as vorinostat, is a USA Food and Drug Administration (FDA) approved HDACi for the treatment of cutaneous T cell lymphoma, and has shown anti-tumour activity in prostate cancer cell lines [69]. In clinical trials as monotherapy, vorinostat did not exhibit anti-tumour activity, and was associated with significant AEs in men with docetaxel-treated CRPC [41]. A phase I trial of oral panobinostat, another HDACi, with or without docetaxel, showed that the dose limiting toxicities were neutropenia and dyspnea, respectively [70]. As evident in cell lines, adding panobinostat to docetaxel showed clinical activity even in patients who previously progressed on docetaxel, providing a suggestion that HDACi may overcome chemotherapy resistance. A phase Ib study with i.v. panobinostat with docetaxel is currently on-going.

Hypomethylating agents have also shown favourable preclinical activity in the treatment of CRPC [71]. 5-Azacitadine, an FDA-approved agent for the treatment of myelodysplastic syndrome, is a potent false substrate competitive inhibitor of methyltransferase via its incorporation into DNA and RNA during cell replication and transcription, leading to silencing of promoter genes. In mouse models, combined treatment with castration and azacitidine delayed time to castration resistance [72]. In 36 patients with chemotherapy naïve CRPC, treatment with azacitidine exhibited acceptable treatment associated AEs (four grade 3 fatigue, two grade 3 neutropenia, and no grade 4 AEs) but only modest in vivo clinical activity [33]. A trial of combined therapy with docetaxel in patients with chemo-naïve CRPC is currently underway.

TOK-001

Galeterone (TOK-001) is the first compound to have multi-functional inhibitory activity on the AR signalling axis. In addition to inhibiting CYP17, TOK-001 is also a very potent inhibitor of adrenal androgens and ARs. A phase I, multicentre, dose-finding study in patients with chemotherapy naïve CRPC was published in the American Society of Clinical Oncology (ASCO) meeting in 2012 [73]. Patients were enrolled in cohorts from 650 to 2600 mg of TOK-001 daily, with 36 of 49 patients completing the 12-week treatment course. The treatment was generally well tolerated, with only one severe AE considered related to TOK-001 (rhabdomyolysis with acute renal failure, with high dose statin use). Overall 22% of treated patients had a >50% PSA level decline, and an additional 26% had 30–50% PSA level declines. Consistent with lyase inhibition, increased corticosteroids and suppressed androgens were seen with dose escalation.

ARN-509

Like its structural analogue of MDV3100, ARN-509 inhibits both AR nuclear translocation and AR binding to androgen response elements in DNA, but with greater efficacy in prostate cancer cells with over-expressed AR [74]. In a pilot phase I study, 30 patients with metastatic CRPC received ARN-509 daily in nine dose escalating cohorts [75]. The most common grades 1–2 treatment-related AEs were fatigue (38%), nausea (29%), and pain (24%), with one treatment-related grade 3 AE (abdominal pain) at 300 mg. At 12 weeks of treatment, 42% of patients have had ≥50% PSA level declines. An optimal biological dose of 240 mg daily was selected for phase II investigation, with PSA response at 12 weeks selected as the primary endpoint [76].

EZN4176

EZN4176, an anti-sense oligonucleotide mRNA antagonist of AR, exhibited potent AR and tumour inhibition in both androgen dependent and independent xenograft models. Upon administration, EZN-4176 is hybridized and releases the complementary sequences of AR mRNA, thus blocking translation of the AR protein, leading to inhibition of AR-induced tumour cell growth, and promotes tumour cell apoptosis in AR over-expressing tumour cells. This therapy has now entered phase I clinical testing.

EPI-001

While nearly all androgen ablative agents target the CTD and its ligand binding region, therapeutic effort against the NTD have recently begun. EPI-001, a small molecule that inhibits transactivation of the AR NTD, has been developed as a promising agent for the treatment of CRPC [77]. The unique mechanism and target of this drug escape several mechanisms of castration resistance such as gain-of-function mutations in the ligand-binding domain, or expression of constitutively active splice variants. This promising approach to targeting of the AR has yet to enter clinical trials.

SUMMARY

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. THE NORMAL PROSTATE AND THE AR
  5. PROSTATE CANCER: THE ROLE OF ANDROGEN AND AR
  6. LIGAND-DEPENDENT MECHANISMS OF CASTRATION RESISTANCE
  7. LIGAND-INDEPENDENT MECHANISMS OF CASTRATION RESISTANCE
  8. NOVEL ENDOCRINE THERAPIES
  9. SUMMARY
  10. CONFLICT OF INTEREST
  11. REFERENCES

For decades, treatment of CRPC has been limited, resulting in dismal outcomes for patients who failed initial hormonal treatment. However, abiraterone and MDV3100 have provided proof that despite castration resistance, more potent and selective agents targeting the androgen–AR signalling axis can be effective. A rich pipeline of novel therapeutic agents is currently in various stages of preclinical and clinical development. Continued efforts to combat mechanisms of AR resistance will be critical to improving prostate cancer outcomes in the future.

REFERENCES

  1. Top of page
  2. Abstract
  3. INTRODUCTION
  4. THE NORMAL PROSTATE AND THE AR
  5. PROSTATE CANCER: THE ROLE OF ANDROGEN AND AR
  6. LIGAND-DEPENDENT MECHANISMS OF CASTRATION RESISTANCE
  7. LIGAND-INDEPENDENT MECHANISMS OF CASTRATION RESISTANCE
  8. NOVEL ENDOCRINE THERAPIES
  9. SUMMARY
  10. CONFLICT OF INTEREST
  11. REFERENCES
  • 1
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277300
  • 2
    Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol 2006; 24: 396402
  • 3
    Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003; 88: 297282
  • 4
    Hayward SW, Cunha GR. The prostate: development and physiology. Radiol Clin North Am 2000; 38: 114
  • 5
    Ohno S. Major sex-determining genes. Monogr Endocrinol 1978; 11: 1140
  • 6
    Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276308
  • 7
    Migliaccio A, Castoria G, Di Domenico M et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 2000; 19: 540617
  • 8
    Kousteni S, Bellido T, Plotkin LI et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001; 104: 71930
  • 9
    Castoria G, Lombardi M, Barone MV et al. Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action. J Cell Biol 2003; 161: 54756
  • 10
    Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001; 93: 168797
  • 11
    Isbarn H, Pinthus JH, Marks LS et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 2009; 56: 4856
  • 12
    Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 2004; 10: 71216
  • 13
    Yang M, Xie W, Mostaghel E et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2011; 29: 256573
  • 14
    Chang KH, Li R, Papari-Zareei M et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 2011; 108: 1372833
  • 15
    Bhanalaph T, Varkarakis MJ, Murphy GP. Current status of bilateral adrenalectomy or advanced prostatic carcinoma. Ann Surg 1974; 179: 1723
  • 16
    Witjes FJ, Debruyne FM, Fernandez del Moral P, Geboers AD. Ketoconazole high dose in management of hormonally pretreated patients with progressive metastatic prostate cancer. Dutch South-Eastern Urological Cooperative Group. Urology 1989; 33: 4115
  • 17
    Fung KM, Samara EN, Wong C et al. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 2006; 13: 16980
  • 18
    Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005; 11: 46537
  • 19
    Stanbrough M, Bubley GJ, Ross K et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 281525
  • 20
    Locke JA, Nelson CC, Adomat HH, Hendy SC, Gleave ME, Guns ES. Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. J Steroid Biochem Mol Biol 2009; 115: 12636
  • 21
    Belanger B, Belanger A, Labrie F, Dupont A, Cusan L, Monfette G. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem 1989; 32: 6958
  • 22
    Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 4016
  • 23
    Koivisto P, Kononen J, Palmberg C et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 3149
  • 24
    Bubendorf L, Kononen J, Koivisto P et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999; 59: 8036
  • 25
    Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 3445
  • 26
    Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61: 28928
  • 27
    Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T, Aoki Y. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 2010; 70: 74554
  • 28
    Culig Z, Klocker H, Eberle J et al. DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 1993; 22: 1122
  • 29
    Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 1998; 152: 19
  • 30
    Fenton MA, Shuster TD, Fertig AM et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997; 3: 13838
  • 31
    Culig Z, Hoffmann J, Erdel M et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999; 81: 24251
  • 32
    Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 156672
  • 33
    Zhao XY, Malloy PJ, Krishnan AV et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000; 6: 7036
  • 34
    Kelly WK. Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Eur Urol 1998; 34 (Suppl. 3): 1823
  • 35
    Gao L, Alumkal J. Epigenetic regulation of androgen receptor signaling in prostate cancer. Epigenetics 2010; 5: 1004
  • 36
    Perry AS, Watson RW, Lawler M, Hollywood D. The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol 2010; 7: 66880
  • 37
    Wang LG, Ossowski L, Ferrari AC. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene 2004; 23: 517584
  • 38
    Karpf AR, Bai S, James SR, Mohler JL, Wilson EM. Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol Cancer Res 2009; 7: 52335
  • 39
    Kraus S, Gioeli D, Vomastek T, Gordon V, Weber MJ. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. Cancer Res 2006; 66: 1104754
  • 40
    Nakayama T, Watanabe M, Suzuki H et al. Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest 2000; 80: 178996
  • 41
    Bradley D, Rathkopf D, Dunn R et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 2009; 115: 55419
  • 42
    Holter E, Kotaja N, Makela S et al. Inhibition of androgen receptor (AR) function by the reproductive orphan nuclear receptor DAX-1. Mol Endocrinol 2002; 16: 51528
  • 43
    Hu R, Dunn TA, Wei S et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69: 1622
  • 44
    Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68: 546977
  • 45
    Watson PA, Chen YF, Balbas MD et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 2010; 107: 1675965
  • 46
    Rocchi P, So A, Kojima S et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004; 64: 6595602
  • 47
    Rocchi P, Beraldi E, Ettinger S et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 2005; 65: 1108393
  • 48
    Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999; 5: 2805
  • 49
    Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55: 443845
  • 50
    Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 2000; 141: 225765
  • 51
    Wang L, Hsu CL, Chang C. Androgen receptor corepressors: an overview. Prostate 2005; 63: 11730
  • 52
    Loy CJ, Sim KS, Yong EL. Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions. Proc Natl Acad Sci U S A 2003; 100: 45627
  • 53
    Gross M, Liu B, Tan J, French FS, Carey M, Shuai K. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene 2001; 20: 38807
  • 54
    Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 456371
  • 55
    Ryan CJ, Smith MR, Fong L et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28: 14818
  • 56
    Attard G, Reid AH, A'Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 37428
  • 57
    Danila DC, Morris MJ, de Bono JS et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496501
  • 58
    de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 19952005
  • 59
    Johnson & Johnson, Inc. Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer. Available at: http://www.jnj.com/connect/news/all/study-unblinded-zytiga-abiraterone-acetate-plus-prednisone-for-asymptomatic-or-mildly-symptomatic-chemotherapy-naive-patients-with-metastatic-castration-resistant-prostate-cancer. Accessed 23 March 2012
  • 60
    Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 339
  • 61
    Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 78790
  • 62
    Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 2010; 375: 143746
  • 63
    Higano CS, Beer TM, Taplin E et al. Antitumor activity of MDV3100 in pre- and post-docetaxel advanced prostate cancer: long-term follow-up of a phase I/II study. J Clin Oncol 2011; 29 (Suppl. 7): abstract 134
  • 64
    Scher HI, Fizazi K, Saad F et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. J Clin Oncol 2012; 30 (Suppl. 5): abstract LBA1
  • 65
    Ahlem C, Kennedy M, Page T et al. 17α-alkynyl 3α, 17β-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism. Invest New Drugs 2012; 30: 5978
  • 66
    Montgomery RB, Morris M, Ryan C et al. Results of preclinical and clinical phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in castrate-resistant prostate cancer. Mol Cancer Ther 2009; 8 (Meeting Abstract Supplement): A221
  • 67
    Montgomery RB, Morris MJ, Ryan CJ et al. HE3235, a synthetic adrenal hormone, in patients with castration-resistant prostate cancer (CRPC): results of phase I/II clinical trial. J Clin Oncol 2010; 28 (Suppl.): 15s, abstracy 4674
  • 68
    Harbor BioSciences Inc. Harbor BioSciences Apoptone® for Prostate Cancer Shows A Partial Overall Response-New Positive Phase I/Iia Data. Weber R ed. Chief Financial Officer, San Diego, California, USA: Harbor BioSciences, Inc., 2010
  • 69
    Welsbie DS, Xu J, Chen Y et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 2009; 69: 95866
  • 70
    Rathkopf D, Wong BY, Ross RW et al. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 2010; 66: 1819
  • 71
    Festuccia C, Gravina GL, D'Alessandro AM et al. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocr Relat Cancer 2009; 16: 40113
  • 72
    Zorn CS, Wojno KJ, McCabe MT, Kuefer R, Gschwend JE, Day ML. 5-aza-2′-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer. Clin Cancer Res 2007; 13: 213643
  • 73
    Montgomery RB, Eisenberger MA, Rettig M et al. Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC). J Clin Oncol 2012; 30 (Suppl.): abstract 4665
  • 74
    Sawyers CL. New insights into the prostate cancer genome and therapeutic implications. Proceedings of the Prostate Cancer Foundation Annual Scientific Retreat, 2010 September 15–16, 2010; Washington DC; 2010. Available at: http://www.pcf.org/atf/cf/%7B7C77D6A2-5859-4D60-AF47-132FD0F85892%7D/PCFStateScience2010.pdf. Accessed 23 March 2012
  • 75
    Rathkopf DE, Morris MJ, Danila DC et al. A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2012; 30 (Suppl.): abstract 4548
  • 76
    Rathkopf DE, Shore N, Antonarakis ES et al. A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol 2012; 30 (Suppl.): abstract TPS4697
  • 77
    Andersen RJ, Mawji NR, Wang J et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010; 17: 53546